

Rahul Ladwa

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4404708/rahul-ladwa-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

29
papers

227
citations

9
h-index

14
g-index

33
ext. papers

399
ext. citations

3.9
avg, IF

3.45
L-index

#	Paper	IF	Citations
29	Expression of CTGF and Cyr61 in colorectal cancer. <i>Journal of Clinical Pathology</i> , 2011 , 64, 58-64	3.9	36
28	Understanding the tumor microenvironment for effective immunotherapy. <i>Medicinal Research Reviews</i> , 2021 , 41, 1474-1498	14.4	32
27	Targeting BRAF mutations in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019 , 8, 1119-1124	4.4	27
26	The cessation of anti-PD-1 antibodies of complete responders in metastatic melanoma. <i>Melanoma Research</i> , 2017 , 27, 168-170	3.3	21
25	Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?. <i>International Journal of Cancer</i> , 2020 , 146, 2305-2314	7.5	19
24	High-Plex and High-Throughput Digital Spatial Profiling of Non-Small-Cell Lung Cancer (NSCLC). <i>Cancers</i> , 2020 , 12,	6.6	11
23	Immune Checkpoint Inhibitors in Cancer Therapy. <i>Current Oncology</i> , 2022 , 29, 3044-3060	2.8	11
22	Investigating and managing suspected pulmonary embolism in an outpatient setting: the Leicester experience. <i>Thorax</i> , 2015 , 70, 291-3	7.3	10
21	Evolution of Cancer Vaccines-Challenges, Achievements, and Future Directions. <i>Vaccines</i> , 2021 , 9,	5.3	9
20	A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC). <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 743-753	7.4	8
19	A Rare Case of Omentum Invasive Prostate Cancer: Staging With PSMA PET/CT Imaging and Response to Systemic Therapy. <i>Clinical Nuclear Medicine</i> , 2017 , 42, e311-e312	1.7	7
18	Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 1278-1284	8.9	7
17	Maintaining Dose Intensity of Adjuvant Chemotherapy in Older Patients With Breast Cancer. <i>Clinical Breast Cancer</i> , 2018 , 18, e1181-e1187	3	7
16	Posterior Reversible Encephalopathy Syndrome in Early-Stage Breast Cancer. <i>Breast Journal</i> , 2015 , 21, 674-7	1.2	5
15	Adenoid cystic carcinoma: a review of clinical features, treatment targets and advances in improving the immune response to monoclonal antibody therapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021 , 1875, 188523	11.2	5
14	Relapse after cessation of PD-1 based therapy for complete responders in metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9536-9536	2.2	3
13	1084P Cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma (mCSCC): Preliminary safety and efficacy results from a phase I clinical trial. <i>Annals of Oncology</i> , 2020 , 31, S736	10.3	2

12	The changing paradigm of management in melanoma brain metastases. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018 , 14, 453-458	1.9	2
11	Tumor Cystic Necrosis Following Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors. <i>Clinical Nuclear Medicine</i> , 2018 , 43, 186-187	1.7	1
10	Quantitative CT texture assessment of tumour heterogeneity to predict those patients with non-small cell lung cancer most likely to benefit from immune checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e21027-e21027	2.2	1
9	High-Plex and High-throughput Digital Spatial Profiling of non-small-cell lung cancer (NSCLC)		1
8	Computed tomography texture analysis of response to second-line nivolumab in metastatic non-small cell lung cancer. <i>Lung Cancer Management</i> , 2020 , 9, LMT38	2.6	1
7	The Feasibility and Tolerability of Newer Chemotherapy Regimens in the Adjuvant Setting in Older Patients with Breast Cancer. <i>Breast Journal</i> , 2016 , 22, 244-6	1.2	1
6	The declining role of post-treatment neck dissection in human papillomavirus-associated oropharyngeal cancer. <i>Radiotherapy and Oncology</i> , 2020 , 151, 242-248	5.3	0
5	Telehealth cancer-related fatigue clinic model for cancer survivors: a pilot randomised controlled trial protocol (the T-CRF trial).. <i>BMJ Open</i> , 2022 , 12, e059952	3	0
4	Culture of circulating tumour cells derived from non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e21692-e21692	2.2	
3	Factors influencing disease control in metastatic lung cancer with intracranial metastasis post gamma-knife radiotherapy.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e21602-e21602	2.2	
2	The feasibility and tolerability of newer chemotherapy regimens in the adjuvant setting in older patients with breast cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e12019-e12019	2.2	
1	Lean thinking: Exploring the volume of overhead and supplementary tasks (OST) in cancer care (CC) in the oncology outpatient encounter (OOE) in two tertiary centres.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 6589-6589	2.2	